Analysis

Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to KURA.

websiteKURA/analysis/KURA

Kura Oncology, Inc.

Kura Oncology, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to KURA.

Stock profile

Ticker

KURA

Asset type

Stock

Market cap

$881.5M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Kura Oncology, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • KURA primary listing
  • KUR
  • A143UH

Latest Kura Oncology, Inc. news

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly dia...

Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule

Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development ...

– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% ...

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R ...

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29%...

Research sections

Valuation

Review valuation context for Kura Oncology, Inc..

Future growth

Review future growth context for Kura Oncology, Inc..

Past performance

Review past performance context for Kura Oncology, Inc..

Financial health

Review financial health context for Kura Oncology, Inc..

Dividend

Review dividend context for Kura Oncology, Inc..

Management

Review management context for Kura Oncology, Inc..

Ownership

Review ownership context for Kura Oncology, Inc..

Other information

Review other information context for Kura Oncology, Inc..

Community

Review community context for Kura Oncology, Inc..